ArticleBreast cancer research and treatment2017
Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results.
Article in Breast cancer research and treatment, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
78 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Management of individuals with germline pathogenic/likely pathogenic variants in CHEK2: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG).Genetics in medicine : official journal of the American College of Medical Genetics · 2023Guideline
- Risk of developing a second primary cancer in male breast cancer survivors: a systematic review and meta-analysis.British journal of cancer · 2022Pooled it
- Postmastectomy Reconstruction in Male Breast Cancer.The breast journal · 2022Pooled it
- Summary ofGenes · 2020Pooled it
- Association Between CHEK2*1100delC and Breast Cancer: A Systematic Review and Meta-Analysis.Molecular diagnosis & therapy · 2018Pooled it
- Male breast cancer: from extrapolated practice to evidence-based care.The oncologist · 2026Review
- Review
- The applicability of the 21-gene assay to inform chemotherapy benefit in lymph node positive hormone receptor positive male breast cancer.Breast cancer research and treatment · 2026Article
- Male Breast Cancer: Growing Insights and Continuing Challenges.Cancer medicine · 2026Review
- Article
- Beyond 1100delC: distinct CHEK2 variants and unique cancer phenotypes in Northeast Brazil.Familial cancer · 2026Article
- Article
- Current Perspectives on Non-Metastatic Male Breast Cancer: Genetics, Biology, and Treatment Advances: A Systematic Review.Cancers · 2025Review
- Cancer spectrum in Mexican patients with the CHEK2 p.(Leu236Pro) variant: a retrospective study.Familial cancer · 2025Article
- Review
- Translational breast cancer research : a journal focusing on translational research in breast cancer · 2025Review
- Germinal pathogenic CHEK2, novel APC and somatic JAK2V617F variants in a young patient with colorectal cancer, atypical leukemia, cerebral tumour and aggressive course.Ecancermedicalscience · 2025Article
- Genome sequencing enhances the diagnostic yield and expands the genetic landscape of male breast cancer.Genetics in medicine open · 2025Article
- Clinically SignificantCancers · 2024Article
- Two recurrent pathogenic/likely pathogenic variants in PALB2 account for half of PALB2 positive families in Slovenia.Human genomics · 2024Article
18 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
purposeGenetic predisposition to male breast cancer (MBC) is not well understood. The aim of this study was to better define the predisposition genes contributing to MBC and the utility of germline multi-gene panel testing (MGPT) for explaining the etiology of MBCs.
methodsClinical histories and molecular results were retrospectively reviewed for 715 MBC patients who underwent MGPT from March 2012 to June 2016.
resultsThe detection rate of MGPT was 18.1% for patients tested for variants in 16 breast cancer susceptibility genes and with no prior BRCA1/2 testing. BRCA2 and CHEK2 were the most frequently mutated genes (11.0 and 4.1% of patients with no prior BRCA1/2 testing, respectively). Pathogenic variants in BRCA2 [odds ratio (OR) = 13.9; p = 1.92 × 10
conclusionThese data suggest that all MBC patients regardless of age of diagnosis, history of multiple primary cancers, or family history of MBC should be offered MGPT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.